Answers are grounded in this paper and cite their sources.
This study did not meet its primary end point of PFS prolongation with cediranib either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma, although cediranib showed evidence of clinical activity on some secondary end points including time to deterioration in neurologic status and corticosteroid-sparing effects.
No takes yet. Share an insight, caveat, or question.
Batchelor et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: